Press "Enter" to skip to content

Mirvetuximab Soravtansine Data Lacking for FDA’s Accelerated Approval in Ovarian CA – Cancer Therapy Advisor

admin 0

Mirvetuximab Soravtansine Data Lacking for FDA’s Accelerated Approval in Ovarian CA  Cancer Therapy Advisor

The FDA has recommended that ImmunoGen, Inc. conduct a new phase 3 randomized trial to evaluate mirvetuximab soravtansine.

“ovarian cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *